APA (7th ed.) Citation

SP, H., J, S., M, C., AL, C., A, K., M, K., . . . S, Q. (2020). IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future oncology (London, England), 16(15), 975. https://doi.org/10.2217/fon-2020-0162

Chicago Style (17th ed.) Citation

SP, Hack, et al. "IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-risk Hepatocellular Carcinoma After Curative Resection or Ablation." Future Oncology (London, England) 16, no. 15 (2020): 975. https://doi.org/10.2217/fon-2020-0162.

MLA (9th ed.) Citation

SP, Hack, et al. "IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-risk Hepatocellular Carcinoma After Curative Resection or Ablation." Future Oncology (London, England), vol. 16, no. 15, 2020, p. 975, https://doi.org/10.2217/fon-2020-0162.